Skip links

News

PharmaCielo logo

PharmaCielo Announces Financial Results for Q2 2020

Revenue continues to accelerate. The Company generated $1.2 million in revenue during Q2-2020, reaching $1.7 Million YTD 2020 compared to $786,901 in its full 2019 fiscal year. Recent increase in active cultivation footprint readies PharmaCielo to process and deliver more extracted product during the second
PharmaCielo contract grower greenhouse

PharmaCielo Increases Cannabis Cultivation Through External Contractor

PharmaCielo Increases Cannabis Cultivation Through External Contractor to Meet Market Demand for Medicinal Extracts Additional area under active cultivation expands PharmaCielo’s immediate footprint by 32 percent to 1.6 million square feet with further expansion pending grower license approval Company activates first external cultivation contract with
PharmaCielo logo

PharmaCielo Ltd. Closes $4.6 Million Bought Deal Offering

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./ TORONTO (July 3, 2020) – PharmaCielo Ltd. (“PharmaCielo” or the “Company“) (TSXV: PCLO) (OTCQX: PCLOF) is pleased to announce that it has closed its previously announced “bought deal” offering (the “Offering“)
PharmaCielo logo

PharmaCielo Ltd. Announces $4,000,000 Bought Deal Public Offering

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ TORONTO (June 10, 2020) – PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) (the “Company” or “PharmaCielo”) is pleased to announce that it has entered into an agreement with a syndicate of investment dealers led by